Nomura Asset Management Co. Ltd. Has $4.17 Million Holdings in Moderna, Inc. (NASDAQ:MRNA)

Nomura Asset Management Co. Ltd. trimmed its holdings in Moderna, Inc. (NASDAQ:MRNA) by 12.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 100,180 shares of the company’s stock after selling 14,155 shares during the period. Nomura Asset Management Co. Ltd.’s holdings in Moderna were worth $4,165,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in the stock. Wilmington Savings Fund Society FSB increased its holdings in Moderna by 295.0% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock valued at $33,000 after buying an additional 587 shares during the period. Compass Planning Associates Inc acquired a new stake in shares of Moderna during the 4th quarter worth approximately $37,000. Venturi Wealth Management LLC increased its stake in Moderna by 286.2% in the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock valued at $37,000 after acquiring an additional 664 shares during the last quarter. Crowley Wealth Management Inc. bought a new stake in Moderna during the fourth quarter worth $41,000. Finally, MassMutual Private Wealth & Trust FSB boosted its holdings in shares of Moderna by 58.2% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock valued at $44,000 after purchasing an additional 389 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Argus downgraded Moderna from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. UBS Group reduced their price target on shares of Moderna from $96.00 to $78.00 and set a “buy” rating on the stock in a research note on Wednesday, February 19th. Evercore ISI set a $50.00 price target on shares of Moderna in a report on Friday, February 14th. JPMorgan Chase & Co. dropped their price objective on shares of Moderna from $40.00 to $33.00 and set an “underweight” rating for the company in a research note on Friday, March 21st. Finally, Barclays cut shares of Moderna from an “overweight” rating to an “equal weight” rating and decreased their target price for the stock from $111.00 to $45.00 in a research note on Tuesday, February 18th. Four equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $59.00.

Moderna Price Performance

NASDAQ:MRNA opened at $27.16 on Wednesday. Moderna, Inc. has a one year low of $26.80 and a one year high of $170.47. The company has a market cap of $10.50 billion, a PE ratio of -2.93 and a beta of 1.86. The firm has a 50-day moving average of $34.43 and a 200-day moving average of $43.55.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.